← Back to Search

Radiation Therapy

Advanced Imaging & Software for Head and Neck Cancer

N/A
Recruiting
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient age ≥ 19
Patient is receiving radiation therapy for cancer of the head and neck involving a target in either the ipsilateral or bilateral neck, with a minimum of 21 fractions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This trial looks at using advanced imaging & software to plan the best treatment for head & neck cancer.

Who is the study for?
This trial is for adults over 19 with head and neck cancer who are set to receive radiation therapy at the NS Health QE2 site. They must be scheduled for a minimum of 21 treatment sessions. Pregnant individuals, those not consenting, or patients with prior treatments like bilateral neck dissection/laryngectomy or radiation to oral cavity/sinuses cannot participate.Check my eligibility
What is being tested?
The study is testing the effectiveness of HyperSight CBCT imaging combined with adaptive planning software in creating real-time and adjusted radiotherapy plans for treating head and neck cancers.See study design
What are the potential side effects?
As this trial focuses on imaging technology rather than medication, side effects may not be as common as drug trials. However, there could be risks associated with additional exposure to radiation from frequent imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 19 years old or older.
Select...
I am undergoing radiation therapy for head or neck cancer with at least 21 treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate potential reduction in time and resources required for offline plan adaptation
Evaluation of CBCT-based dosimetry calculations
Improvements in radiation dosimetry from using online adaptation
+1 more
Secondary outcome measures
CBCT image quality
Patient experience questionnaire

Trial Design

1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging ArmExperimental Treatment1 Intervention
Subjects imaged with the new HyperSight CBCT imaging system.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBCT Imaging
2022
N/A
~30

Find a Location

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyLead Sponsor
30 Previous Clinical Trials
7,243 Total Patients Enrolled

Media Library

On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05666193 — N/A
Head and Neck Cancers Research Study Groups: HyperSight Imaging Arm
Head and Neck Cancers Clinical Trial 2023: On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software Highlights & Side Effects. Trial Name: NCT05666193 — N/A
On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05666193 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities currently available for prospective participants?

"Clinicaltrials.gov confirms that enrollment for this medical trial is currently suspended, having been initially posted on March 1st 2023 and last updated December 16th 2022. However, 476 other trials are actively searching for participants at the present moment."

Answered by AI
~3 spots leftby May 2024